AstraZeneca PLC (ZEGA) — Capital Reinvestment Ratio
AstraZeneca PLC (ZEGA) has a Capital Reinvestment Ratio of 0.34x as of September 2025, meaning it reinvests 0% of its operating cash flow (€5.13 Billion) in capital expenditures (€1.73 Billion). Check ZEGA intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
AstraZeneca PLC Capital Reinvestment Ratio (2014–2024)
This chart tracks AstraZeneca PLC's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of AstraZeneca PLC.
Annual Capital Reinvestment Ratio for AstraZeneca PLC (2014–2024)
Year-by-year Capital Reinvestment Ratio for AstraZeneca PLC from 2014 to 2024. See ZEGA free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.39x | €11.86 Billion | €4.59 Billion | ▲ +18.3% |
| 2023 | 0.33x | €10.36 Billion | €3.39 Billion | ▲ +193.7% |
| 2022 | 0.11x | €9.81 Billion | €1.09 Billion | ▼ -39.2% |
| 2021 | 0.18x | €5.96 Billion | €1.09 Billion | ▼ -8.6% |
| 2020 | 0.20x | €4.80 Billion | €961.00 Million | ▼ -39.3% |
| 2019 | 0.33x | €2.97 Billion | €979.00 Million | ▼ -17.2% |
| 2018 | 0.40x | €2.62 Billion | €1.04 Billion | ▲ +7.5% |
| 2017 | 0.37x | €3.58 Billion | €1.33 Billion | ▼ -33.6% |
| 2016 | 0.56x | €4.14 Billion | €2.31 Billion | ▲ +39.7% |
| 2015 | 0.40x | €3.32 Billion | €1.33 Billion | ▲ +178.6% |
| 2014 | 0.14x | €7.06 Billion | €1.01 Billion | — |